Theravance Biopharma
TBPH
TBPH
104 hedge funds and large institutions have $1.1B invested in Theravance Biopharma in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less capital invested
Capital invested by funds: $1.22B → $1.1B (-$121M)
98% less call options, than puts
Call options by funds: $220K | Put options by funds: $13.3M
Holders
104
Holding in Top 10
1
Calls
$220K
Puts
$13.3M
Top Buyers
| 1 | +$24.1M | |
| 2 | +$2.39M | |
| 3 | +$2.13M | |
| 4 |
JG
Jefferies Group
New York
|
+$2.08M |
| 5 |
Parallax Volatility Advisers
San Francisco,
California
|
+$1.83M |
Top Sellers
| 1 | -$22.6M | |
| 2 | -$3.32M | |
| 3 | -$2.31M | |
| 4 |
D.E. Shaw & Co
New York
|
-$911K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$556K |